Previous 10 | Next 10 |
I have always found that mercy bears richer fruits than strict justice ." - Abraham Lincoln We continue our series of reviews of Q2 results at previously profiled small biotech concerns today. In today's post, we revisit Theravance Biopharma ( TBPH ) whose stock has been on a nice little ...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...
Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Conference Call July 31, 2019, 08:00 ET Company Participants Jessica Stitt - Former VP, Finance and IR Rick Winningham - Chairman & CEO Brett Haumann - SVP, Clinical Development & Chief Medical Officer Frank Pasqualone ...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Theravance Biopharma (NASDAQ: TBPH ): Q2 GAAP EPS of -$0.72 beats by $0.50 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , July 31, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ended June 30, 2019 . Revenue for the second quarter of 2019 was $26.2 million . Second quarter operating lo...
DUBLIN , July 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended June 30, 2019 and provide a business update prior to market open on Wednesday, July 31,...
Krones I've been following Krones ( KRNNF ) ( KRNTY ) for many years. This German hidden champion (EUR 1.7B market cap, free float <45% of this) builds large and small plants for filling and packaging, process engineering, and intralogistics as well as IT solutions for the food and bevera...
New data from a Phase 2 clinical trial evaluating Theravance Biopharma's ( TBPH +1.9% ) ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) showed a treatment benefit. The results were presented at the European Neurology Congress in London. More news on: ...
DUBLIN , July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...